Astrana Health (ASTH) Earnings Analysis
Astrana Health (ASTH) next reports earnings on 2026-08-06, consensus EPS 0.33 USD. Last quarter (2026-05-07) it beat with EPS 0.3 USD vs 0.29 USD est (+3.4%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 67.91.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ASTH next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 0.33 USD |
| Revenue estimate | 0.99B |
ASTH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.3 USD | 0.29 USD | +3.4% | Beat |
| 2026-03-02 | 0.54 USD | 0.15 USD | +260% | Beat |
| 2025-11-06 | 0.01 USD | 0.47 USD | -97.9% | Miss |
| 2025-08-07 | 0.19 USD | 0.36 USD | -47.2% | Miss |
| 2025-05-08 | 0.14 USD | 0.23 USD | -39.1% | Miss |
| 2025-02-27 | -0.15 USD | 0.22 USD | -168.2% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
ASTH valuation and analyst view
| Trailing P/E | 67.91 |
|---|---|
| Trailing EPS | 0.61881 USD |
| Price / book | 2.56 |
| Dividend yield | 0.00% |
| Market cap | 2.15B |
| Analyst consensus | Buy (10 buy / 0 hold / 0 sell) |
| Avg price target | 47.5 USD |
Related research pages
Frequently asked questions
When is Astrana Health (ASTH)'s next earnings date?
Astrana Health is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.33 USD and revenue estimate of 0.99B.
Did ASTH beat earnings last quarter?
In its 2026-05-07 report, ASTH posted EPS of 0.3 USD versus a 0.29 USD estimate — a beat of 3.4%.
What is ASTH's earnings track record?
Over the last 6 reported quarters with consensus data, ASTH beat estimates 2 times (33%).
What is ASTH's current P/E ratio and EPS?
ASTH trades at a trailing P/E of 67.91 on trailing EPS of 0.6188070425321918 USD.
What do analysts rate ASTH?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 47.5 USD.